- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 2 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 11.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase ... | 233 | PR Newswire | SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the... ► Artikel lesen | |
| 06.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Intensity Therapeutics GAAP EPS of -$0.22 | 2 | Seeking Alpha | ||
| 13.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 45 | PR Newswire | Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated
European Medicines Agency Authorization to initiate INVINCIBLE-4-Study... ► Artikel lesen | |
| 13.05. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 25.04. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | Why Intensity Therapeutics (INTS) Stock Is Getting Hammered | 3 | Benzinga.com | ||
| 25.04. | Intensity Therapeutics plunges on $2.35M public offering | 2 | Seeking Alpha | ||
| 25.04. | Intensity Therapeutics legt Bedingungen für Angebot über 2,35 Millionen US-Dollar fest | 2 | Investing.com Deutsch | ||
| 24.04. | INTENSITY THERAPEUTICS, INC. - S-1/A, General form for registration of securities | 6 | SEC Filings | ||
| 22.04. | INTENSITY THERAPEUTICS, INC. - S-1, General form for registration of securities | 5 | SEC Filings | ||
| 19.03. | Benchmark maintains Speculative Buy on Intensity Therapeutics | 1 | Investing.com | ||
| 13.03. | Intensity Therapeutics GAAP EPS of -$1.17 in-line | 1 | Seeking Alpha | ||
| 13.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update | 505 | PR Newswire | 32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened
Eight Swiss sites are activated in the INVINCIBLE-4 Study, and... ► Artikel lesen | |
| 13.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| EDITAS MEDICINE | 1,924 | -1,00 % | Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? | ||
| GINKGO BIOWORKS | 7,750 | -3,73 % | Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development | ||
| NOVOCURE | 14,945 | -2,86 % | Demystifying NovoCure: Insights From 4 Analyst Reviews | ||
| ADAPTIMMUNE THERAPEUTICS | 0,206 | -0,96 % | Mizuho downgrades Adaptimmune stock on solvency concerns | ||
| ADVERUM BIOTECHNOLOGIES | 2,100 | -3,67 % | Adverum Biotechnologies price target lowered to $12 at Mizuho | ||
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,31 % bei einem Aktienkurs von 0,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.